文献速递功能神经外科

皮下三叉神经刺激辅助治疗重性单相抑郁障碍的双盲随机试验

Double Blinded Randomized Trial of Subcutaneous Trigeminal Nerve Stimulation as Adjuvant Treatment for Major Unipolar Depressive Disorder.
PubMed 文献 · Neurosurgery · 2019-01-01

TREND研究为单中心、双盲、随机对照II期临床试验,计划纳入20例难治性单相抑郁障碍患者,在药物治疗基础上接受V1区皮下三叉神经刺激(sTNS),随机分为活性刺激组与假刺激组,持续24周,随后24周开放标签期。主要结局为HAM-17抑郁评分改善,预期活性刺激对应答率和缓解率有显著影响,手术和电刺激可能引起轻微副作用,开放标签期进一步确认疗效和耐受性。

要点

  • TREND研究评估皮下三叉神经刺激辅助治疗难治性抑郁的疗效与安全性。
  • 20例患者随机接受活性或假刺激24周,后接24周开放标签期。
  • 主要结局为HAM-17评分改善,预期活性刺激影响应答率和缓解率。

核心结论

  • 该研究方案旨在明确一种新型辅助疗法对难治性抑郁障碍的疗效,需开发安全、可重复、可预测且耐受性好的神经调控方法。

研究设计与样本

  • TREND研究为单中心、双盲、随机对照II期临床试验,计划纳入20例单相难治性抑郁障碍患者,随机分为活性刺激组与假刺激组,在药物治疗基础上接受V1区皮下三叉神经刺激24周,随后24周开放标签期。

主要发现

  • 主要结局指标为持续皮下三叉神经刺激辅助抗抑郁药治疗下HAM-17抑郁评分的改善。
  • 预期活性刺激对应答率和缓解率有显著影响。
  • 预期手术操作和电刺激会引起轻微副作用。
  • 开放标签期应进一步确认疗效和耐受性。

关键数值与推荐

  • 使用HAM-17、BDI-SR、IDS_SR30和UKU量表记录疗效、安慰剂反应、复发及手术或电刺激相关副作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: More than 30% of major depressive disorder patients fail to respond to adequate trials of medications and psychotherapy. While modern neuromodulation approaches (ie, vagal nerve stimulation, deep brain stimulation) are yet to prove their efficacy for such cases in large randomized controlled trials, trigeminal nerve stimulation (TNS) has emerged as an alternative with promising effects on mood disorders. OBJECTIVE: To assess efficacy, safety, tolerability, and placebo effect duration of continuous subcutaneous TNS (sTNS) in treatment-resistant depression (TRD). METHODS: The TREND study is a single-center, double-blind, randomized, controlled, phase II clinical trial. Twenty unipolar TRD patients will receive V1 sTNS as adjuvant to medical therapy and randomized to active vs sham stimulation throughout a 24-wk period. An additional 24-wk open-label phase will follow. Data concerning efficacy, placebo response, relapse, and side effects related to surgery or electrical stimulation will be recorded. We will use the HDRS-17, BDI-SR, IDS_SR30, and UKU scales. EXPECTED OUTCOMES: The main outcome measure is improvement in depression scores using HAM-17 under continuous sTNS as adjuvant to antidepressants. Active stimulation is expected to significantly impact response and remission rates. Minor side effects are expected due to the surgical procedure and electrical stimulation. The open-label phase should further confirm efficacy and tolerability. DISCUSSION: This study protocol is designed to define efficacy of a novel adjuvant therapy for TRD. We must strive to develop safe, reproducible, predictable, and well-tolerated neuromodulation approaches for TRD patients impaired to manage their lives and contribute with society.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Gorgulho AA, Fernandes F, Damiani LP, et al. Double Blinded Randomized Trial of Subcutaneous Trigeminal Nerve Stimulation as Adjuvant Treatment for Major Unipolar Depressive Disorder. Neurosurgery. 2019. PMID: 30272245. doi:10.1093/neuros/nyy420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。